Definium Therapeutics Sees Unusually High Options Volume (NASDAQ:DFTX)

Definium Therapeutics, Inc. (NASDAQ:DFTX) was the target of some unusual options trading activity on Monday. Traders purchased 6,567 put options on the stock. This is an increase of approximately 68% compared to the typical volume of 3,899 put options.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported that its second Phase 3 study of DT120 ODT met its primary endpoint, showing a statistically significant improvement in anxiety symptoms among patients with generalized anxiety disorder. The result confirms the positive findings from the earlier late-stage study and reduces clinical-development risk. Definium’s LSD-based drug lowers anxiety in second successful late-stage study
• Positive Sentiment: Coverage of the Panorama Phase 3 trial highlighted significant anxiety improvement and described the data as a successful readout, helping drive renewed investor interest in DFTX. Definium Says Second Phase 3 DT120 Study in Generalized Anxiety Disorder Meets Goal
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $70 price target, while Needham reaffirmed its “buy” rating with a $66 target. Both targets imply substantial upside from recent trading levels and indicate continued analyst confidence in DT120’s prospects.
• Positive Sentiment: Definium’s shares rallied as investors anticipated—and then reacted to—the Phase 3 results, with trading temporarily halted for pending news before the clinical announcement.
• Neutral Sentiment: The company granted stock options covering 56,650 shares to three newly hired, non-executive employees. The grants support hiring but could modestly increase future share dilution. Definium Therapeutics Announces New Employee Inducement Grants

Insider Buying and Selling at Definium Therapeutics

In related news, CEO Robert Barrow sold 29,208 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the sale, the chief executive officer owned 1,098,246 shares in the company, valued at $49,454,017.38. This represents a 2.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Brandi Roberts sold 3,013 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the transaction, the chief financial officer directly owned 209,487 shares in the company, valued at approximately $9,433,199.61. The trade was a 1.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 67,119 shares of company stock valued at $2,887,496 over the last ninety days. 2.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Definium Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Nykredit A S bought a new stake in shares of Definium Therapeutics during the 2nd quarter worth $45,000. Cerity Partners LLC increased its position in shares of Definium Therapeutics by 2.4% during the second quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock valued at $322,000 after buying an additional 1,165 shares during the period. Creative Planning lifted its stake in shares of Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares during the period. Russell Investments Group Ltd. grew its position in shares of Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the period. Finally, Mercer Global Advisors Inc. ADV increased its stake in shares of Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after purchasing an additional 2,079 shares in the last quarter. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DFTX has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Friday, July 17th. Robert W. Baird raised their price target on shares of Definium Therapeutics from $57.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Piper Sandler reissued an “overweight” rating and set a $75.00 target price (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $66.00 price target on shares of Definium Therapeutics in a research report on Friday. Finally, Oppenheimer reiterated an “outperform” rating and set a $70.00 price target on shares of Definium Therapeutics in a report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $63.00.

Definium Therapeutics Stock Performance

Shares of NASDAQ:DFTX traded up $1.70 during mid-day trading on Monday, reaching $40.59. The company had a trading volume of 4,431,703 shares, compared to its average volume of 2,238,051. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The firm has a market cap of $5.45 billion, a price-to-earnings ratio of -11.83 and a beta of 2.23. The company’s 50-day moving average price is $43.01 and its 200-day moving average price is $30.33. Definium Therapeutics has a one year low of $8.77 and a one year high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, equities research analysts anticipate that Definium Therapeutics will post -3.02 EPS for the current fiscal year.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.